Mixtard 30 (Insulin Human)

Insulin human, the active ingredient in Mixtard 30, is an insulin presented as a 100 U/mL premixed insulin injection solution for subcutaneous use. It treats hyperglycaemia in patients with type 1 and type 2 diabetes mellitus.

GNH USA supplies Mixtard 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Mixtard 30 is a premixed insulin used in the management of diabetes mellitus, a disorder of glucose regulation.

- Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve target blood glucose levels. - Type 2 diabetes mellitus: assists patients who need additional insulin to reach glycaemic goals when oral agents are insufficient. - Insulin deficiency (e.g., after pancreatectomy): supplies the necessary exogenous insulin to replace absent endogenous production.

Mixtard 30 may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in fat tissue at injection sites. - Edema: mild swelling of the extremities.

Serious or Rare Side Effects: - Severe hypoglycaemia leading to seizures or loss of consciousness. - Allergic reactions including anaphylaxis, urticaria, or angio‑edema. - Insulin antibody formation that may alter insulin effectiveness. - Acute respiratory distress in rare hypersensitivity cases. - Necrotising fasciitis at the injection site (extremely rare).

When using Mixtard 30, clinicians and patients should observe several safety measures.

- Blood glucose monitoring: check levels regularly to adjust dose and avoid hypoglycaemia. - Dose adjustment during illness: illness or stress may increase insulin requirements. - Caution with renal or hepatic impairment: reduced clearance can heighten hypoglycaemia risk. - Avoid mixing with other insulin preparations unless specifically instructed. - Use with beta‑blockers carefully: they may mask hypoglycaemic symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin therapy can be affected by several concomitant medicines. Interactions are grouped by clinical significance.

Major Interactions (Avoid): - Sulfonylureas: additive hypoglycaemic effect. - Meglitinides: increased risk of severe hypoglycaemia. - Beta‑blockers: may conceal hypoglycaemia warning signs.

Moderate Interactions (Monitor Closely): - Corticosteroids: can raise blood glucose, requiring dose increase. - Thiazide diuretics: may cause modest hyperglycaemia. - Oral contraceptives: may slightly reduce insulin sensitivity.